Oncologists pleased with new treatments for lymphoma, lung cancer, urothelial cancer
Click Here to Manage Email Alerts
Key takeaways:
- Creation Healthcare analyzed 1,462 English language posts on X by 1,050 health care professionals.
- Health care professionals celebrated the approval of new cancer treatments, including tarlatamab-dlle.
An analysis of the online conversations of more than 1,000 health care professionals worldwide through May revealed positive reactions to the approval of three key treatment options for patients with cancer.
Research by Creation Healthcare — a leading digital insights consultancy — showed that health care professionals (HCPs) were “pleased” with the approvals of several treatment options throughout the month, including those for patients with extensive-stage small cell lung cancer (SCLC), follicular and elapsed/refractory mantle cell lymphoma, and unresectable or metastatic urothelial carcinoma.
On May 16, the FDA granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen) for the treatment of patients with extensive-stage SCLC. A number of HCPs proactively used their online platform to share their thoughts on the news.
Misty Dawn Shields, MD, PhD, translational thoracic oncologist and assistant professor of clinical medicine at Indiana University School of Medicine, described the treatment’s approval as a “HUGE victory” for the SCLC treatment space. Quoting this post, Luis E. Raez, MD, medical director and chief scientific officer at Memorial Cancer Institute, labeled it “great news for [our] patients.”
Reflecting much of the same sentiment, Christine M. Lovly, MD, PhD, associate professor of medicine at Vanderbilt University Medical Center, described the news as “practice changing,” and suggested that the approval represented a “much needed advance” in the field. In a follow-up post, however, she called on those celebrating the news to “pause to remember the [patients] with SCLC who were the true pioneers,” adding that it was their “time, devotion [and] belief in the hope of research [that] made this advance possible.”
Several other HCPs with a significant social media presence, including Vivek Subbiah, MD, chief of early-phase drug development at Sarah Cannon Research Institute, and Rami Manochakian, MD, FASCO, thoracic medical oncologist at Mayo Clinic in Jacksonville, Florida, also shared news of the approval on their accounts in posts that reflected a sense of excitement at tarlatamab’s future role in the SCLC treatment space.
In addition, Creation Healthcare used their CREATION Pinpoint technology to analyze 1,462 English language posts on X (formerly Twitter) by 1,050 HCPs from May, aiming to identify and evaluate the key topics discussed relating to FDA approvals and launches of pharmaceutical products.
Beyond the approval of tarlatamab, Creation also listened to conversation surrounding lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb), known as liso-cel, which was approved for the treatment of follicular lymphoma on May 15, and for the treatment of relapsed/refractory mantle cell lymphoma on May 29.
HCPs welcomed both approvals. For example, Alan Skarbnick, MD, of Novant Health, shared the FDA’s press release on the approval, adding that he was “happy to have another CAR-T option for patients!”
Regarding the mantel cell lymphoma indication, Ajay Major, MD, MBA, of University of Colorado School of Medicine, posted that it was “great to have a [treatment] option with less high-grade [cytokine release syndrome] and [immune effector cell-associated neurotoxicity syndrome.]”
On May 29, Bristol Myers Squibb announced that the European Commission had approved their treatment, nivolumab (Opdivo), in combination with cisplatin and gemcitabine for the first-line treatment of patients with unresectable or metastatic urothelial carcinoma.
Two highly followed doctors, Yüksel Ürün, MD, of Ankara University School of Medicine, and Tom Powles, MBBS, MRCP, MD, of Barts Cancer Centre, immediately shared the news with their respective online networks. The latter’s post, which offered insight into guidelines and response rates, gained particular attention online. Collectively, both posts received hundreds of likes, comments and shares.
Throughout May, the three stories most shared by HCPs online were an FDA press release on the accelerated approval of tarlatamab, an OncLive news article on the approval of liso-cel, and a Bristol Myers Squibb press release referring to the approval of nivolumab in combination with cisplatin and gemcitabine.
References:
- Ajay Major, MD, MBA (@majorajay). May 30, 2024. X (Twitter).
- Alan Skarbnick, MD (@ASkarbnik). May 15, 2024. X (Twitter).
- Better listening for better health. https://creation.co/. Accessed May 20, 2024.
- Bristol Myers Squibb receives European Commission approval for Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (press release). https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-in-Combination-with-Cisplatin-and-Gemcitabine-for-the-First-Line-Treatment-of-Adult-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma/default.aspx. Published May 29, 2024. Accessed June 12, 2024.
- Christine Lovly, MD, PhD (@christine_lovly). May 16, 2024. X (Twitter).
- Christine Lovly, MD, PhD (@christine_lovly). May 16, 2024. X (Twitter).
- FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer (press release). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer. Published May 16, 2024. Accessed June 12, 2024.
- FDA approves liso-cel for relapsed/refractory mantle cell lymphoma after 2 lines of therapy (press release). https://www.onclive.com/view/fda-approves-liso-cel-for-r-r-mantle-cell-lymphoma-after-2-lines-of-therapy. Published May 30, 2024. Accessed June 12, 2024.
- Luis E Raez, MD (@LuisRaezMD). May 16, 2024. X (Twitter).
- Misty Dawn Shields, MD, PhD (@drshieldsmd). May 16, 2024. X (Twitter).
- Rami Manochakian, MD, FASCO (@RManochakian). May 16, 2024. X (Twitter).
- Tom Powles, MBBS, MRCP, MD (@tompowles1). May 29, 2024. X (Twitter).
- Vivek Subbiah, MD (@VivekSubbiah). May 16, 2024. X (Twitter).
- Yüksel Ürün, MD (@DrYukselUrun). May 29, 2024. X (Twitter).
Collapse
Read more about
Click Here to Manage Email Alerts